TRIPLET combined with microwave ablation: A novel treatment for advanced hepatocellular carcinoma.

This editorial comments on a study by Zuo . The focus is on the efficacy of hepatic arterial infusion chemotherapy combined with camrelizumab and apatinib (the TRIPLET regimen), alongside microwave ablation therapy, in treating advanced hepatocellular carcinoma (HCC). The potential application of this combination therapy for patients with advanced HCC is evaluated.

Unresectable hepatocellular carcinoma: Transarterial chemoembolization combined with lenvatinib in combination with programmed death-1 inhibition is a possible approach.

In this editorial, we review the article "Efficacy and predictive factors of transarterial chemoembolization combined with lenvatinib plus programmed cell death protein-1 inhibition for unresectable hepatocellular carcinoma". We specifically focused on whether transarterial chemoembolization combined with lenvatinib in combination with a programmed death 1 inhibitor could be used in patients with unresectable hepatocellular carcinoma. Since both transarterial chemoembolization as well as lenvatinib in combination with programmed death 1 inhibitors play an important role in the treatment of advanced liver cancer, but the combination of all three therapeutic approaches needs more research.

[Design and application of an extension tube for ventilator pipeline].

At present, the extension tube of the ventilator, a long corrugated tube used in clinical practice, needs to be disconnected from the endotracheal tube when performing open sputum suction. Under positive pressure, the condensed water containing pathogenic microorganisms in the ventilator will be splashed. Some will form aerosol suspended in the air, pollute the air, increase the risk of cross-infection and operator pollution, while the ventilator will emit a corresponding alarm sound, resulting in noise pollution.

A prediction model of delayed graft function in deceased donor for renal transplant: a multi-center study from China.

Background: Kidneys obtained from deceased donors increase the incidence of delayed graft function (DGF) after renal transplantation. Here we investigated the influence of the risk factors of donors with DGF, and developed a donor risk scoring system for DGF prediction.

Methods: This retrospective study was conducted in 1807 deceased kidney donors and 3599 recipients who received donor kidneys transplants in 29 centers in China.